Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.
This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.
This week we look at the treatment of depression in hemodialysis patients. It is cognitive behavorial therapy versus sertraline.